Lipid profile is significantly associated with sarcopenia status in elderly patients with metabolic syndrome

An Evidence-Based Review of Exercise and Metabolic Syndrome

Is there a relationship between serum uric acid and fructose levels in polycystic ovary syndrome (PCOS)? Elevated serum uric acid levels in women with PCOS positively correlate with serum fructose levels, and elevated serum fructose levels are an independent risk factor for hyperuricemia in women with PCOS. Our previous study suggested a link between elevated serum fructose levels and PCOS. Fructose is unique as it generates uric acid during metabolism, and high uric acid levels are associated with metabolic disorders and an increased risk of anovulation. However, the relationship between serum uric acid and fructose levels in women with PCOS remains unclear. In a case-control study of 774 women (482 controls and 292 patients with PCOS) between May and October 2020 at the Shengjing Hospital of China Medical University, the relationship between uric acid and fructose levels in women with PCOS was examined. Participants were divided into subgroups based on various factors, including BMI, insulin resistance, dyslipidemia, metabolic syndrome, and hyperuricemia. Serum uric acid concentrations were measured using enzymatic assays, and serum fructose levels were determined using a fluorescent enzyme immunoassay. Dietary fructose data were collected through a validated food-frequency questionnaire of 81 food items. We applied restricted cubic splines to a flexibly model and visualized the linear/nonlinear relationships between serum uric acid and fructose levels in PCOS. Multivariate logistic analysis was executed to assess the association between serum fructose levels and hyperuricemia in PCOS. Human granulosa cell and oocyte mRNA profile sequencing data were downloaded for mapping uric acid and fructose metabolism genes in PCOS. Further downstream analyses, including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes analysis, and protein-protein interactions were then carried out on the differentially expressed genes (DEGs). The correlation between uric acid and fructose metabolism genes was calculated using the Pearson correlation coefficient. The GeneCards database was used to identify DEGs related to uric acid and fructose metabolism in PCOS, and then several DEGs were confirmed by quantitative real-time PCR. Both serum fructose and uric acid levels were significantly increased in women with PCOS compared with the control women (P < 0.001), and there was no statistically significant difference in dietary fructose intake between PCOS and controls, regardless of metabolic status. There was a positive linear correlation between serum uric acid and fructose levels in women with PCOS (Poverall < 0.001, Pnon-linear = 0.30). In contrast, no correlation was found in control women (Poverall = 0.712, Pnon-linear = 0.43). Additionally, a non-linear association was observed in the obese subgroup of patients with PCOS (Poverall < 0.001, Pnon-linear = 0.02). Serum uric acid levels were linearly and positively associated with serum fructose levels in patients with PCOS with insulin resistance, dyslipidemia, and metabolic syndrome. Furthermore, even after adjusting for confounding factors, elevated serum fructose levels were an independent risk factor for hyperuricemia in patients with PCOS (P = 0.001; OR, 1.380; 95% CI, 1.207-1.577). There were 28 uric acid and 25 fructose metabolism genes which showed a significant correlation in PCOS. Seven upregulated genes (CAT, CRP, CCL2, TNF, MMP9, GCG, and APOB) related to uric acid and fructose metabolism in PCOS ovarian granulosa cells were ultimately successfully validated using quantitative real-time PCR. Due to limited conditions, more possible covariates (such as smoking and ethnicity) were not included, and the underlying molecular mechanism between fructose and uric acid levels in women with PCOS remains to be further investigated. The results of this study and our previous research indicate that the high uric acid status of PCOS may be mediated by fructose metabolism disorders, highlighting the importance of analyzing fructose metabolism, and especially its metabolic byproduct uric acid, during the clinical diagnosis of PCOS. These results suggest the adverse effects of high uric acid in PCOS, and the importance of taking early interventions regarding uric acid levels to reduce the occurrence and development of further clinical signs, such as metabolic disorders in women with PCOS. This work was supported by: the National Natural Science Foundation of China (No. 82371647, No. 82071607, and No. 32100691); LiaoNing Revitalization Talents Program (No. XLYC1907071); Fok Ying Tung Education Foundation (No. 151039); and Outstanding Scientific Fund of Shengjing Hospital (No. 202003). No competing interests were declared. N/A.

Multi Drug Resistant Tuberculosis (MDR-TB) is a type of tuberculosis that is resistant to two first-line antituberculosis drugs (OAT), namely Isoniazid and Rifampicin. MDR-TB treatment involves a combination of first-line and second-line OAT, which is carried out over a long period of time. The prolonged use of these drugs can cause side effects that affect various organs of the body, especially the kidneys. One indication of impaired kidney function is an increase in blood levels of ureum, uric acid, creatinine and albumin. In addition, side effects of drugs such as Kanamycin, which is nephrotoxic, can cause accumulation in the proximal tubules of the kidneys, reduce the glomerular filtration rate, and impact creatinine levels. Another side effect that can arise during MDR-TB treatment is a decrease in appetite, which leads to decreased nutritional intake, reflected in low albumin levels. This study aims to describe the levels of ureum, uric acid, creatinine, and albumin in patients with MDR-TB undergoing treatment at Ario Wirawan Lung Hospital (RSPAW) Salatiga. This study is descriptive qualitative with a cross-sectional approach. Secondary data were collected from the medical record installation from January to December 2023. This study involved 28 respondents, of which 92.86% had normal ureum levels, 71.43% had normal uric acid levels, 96.43% had normal creatinine levels, and 78.57% had normal albumin levels. A small proportion of respondents had elevated ureum or uric acid levels, with some variation in the combination of abnormal creatinine and albumin levels. The conclusion of this study is that although there were patients with abnormal ureum, uric acid, creatinine, or albumin levels, MDR-TB treatment generally did not significantly affect ureum, uric acid, creatinine, and albumin levels in the majority of patients. However, regular monitoring of renal function and nutritional status is still required to detect and manage adverse effects that may arise during long-term treatment.

Introduction: a relationship has been observed between elevated levels of liver enzymes and uric acid with the presence of metabolic syndrome (MS) in the pediatric population. Objective: to compare serum liver enzyme and uric acid levels between adolescents with and without MS. Methods: a cross-sectional study was carried out in adolescents with obesity between 10 and 18 years old. Somatometric data, serum insulin, lipid profile, uric acid levels and liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT] and gamma-glutamyl transferase [GGT]) were analyzed. Statistical analysis: Student's t test or the Chi-square test was used to evaluate differences between groups. Results: a total of 1095 adolescents with obesity were included (444 with MS and 651 without MS). The group with MS had a higher BMI (with MS 2.28 vs without MS 2.11 p < 0.001), with no difference in body fat (42.9 % vs 42.9 %, p = 0.978). The MS group had significantly higher levels of AST (34.4 vs. 29.5, p = 0.013), ALT (42.2 vs. 34.6, p = 0.003), and uric acid (6.17 vs. 5.74, p = 0.002). comparison to the group without MS. The proportion of ALT (40.5 % vs 29.5 %, p = 0.029) and altered uric acid (58.1 % vs. 45.6 %, p = 0.019) was higher in the MS group. Conclusions: serum levels of ALT, AST and uric acid in adolescents with obesity and MS were higher compared to those without MS. Altered ALT was a risk factor for SM.

Background: This study aimed to conduct an analysis of longitudinal study to investigate the association of absolute grip strength, and relative grip strength with incidence of metabolic syndrome. Materials and Methods: Participants who participated in the Korean Genome and Epidemiology Study, a chronic screening program conducted in Ahnseong-si, Gyeonggi-do, a primary survey conducted from 2013 to 2014 were selected. The presence of metabolic syndrome was classified using the standards of the International Diabetes Foundation following previous studies. Grip strength was measured using a JAMA 5030J1 (Saehan, Korea) and calculated the absolute grip strength and relative grip strength. To evaluate the relationship between the absolute grip strength, relative grip strength, and incidence of metabolic syndrome, independent hazard ratios (HRs) and 95% confidence intervals (CIs) for metabolic syndrome were calculated according to absolute and relative grip strength levels using a multivariate extended Cox regression model. Results: The incidence of metabolic syndrome was reduced by 38% (HR = 0.62, 95% CI = 0.43-0.88) for the high absolute grip strength group, compared to the low absolute grip strength group. Also, this study confirmed that the incidence of metabolic syndrome for mid relative grip strength and high relative grip strength groups were reduced by 27% (HR = 0.73, 95% CI = 0.55-0.98) and 55% (HR = 0.45, 95% CI = 0.32-0.64) respectively. Moreover, the incidence of metabolic syndrome was reduced by 45% (HR = 0.55, 95% CI = 0.37-0.82) and 57% (HR = 0.43, 95% CI = 0.29-0.65) for the low-level body mass index (BMI) group with high or low absolute grip strength, respectively. Finally, this study confirmed the association of sex, absolute grip strength, and relative grip strength according to age with incidence of metabolic syndrome was different. Conclusion: We observed that relative grip strength has a higher association with incidence of metabolic syndrome than absolute grip strength. Also, BMI has a higher association with metabolic syndrome than the absolute grip strength.

Sarcopenia is common in hemodialysis patients, especially in the elderly patients undergoing hemodialysis. Various factors may contribute to the occurrence of sarcopenia, such as anabolic and catabolic imbalance. This study aims to investigate the correlation of insulin-like growth factor-1 (IGF-1) levels as an anabolic factor, myostatin levels, and insulin resistance as catabolic factors with sarcopenia in the pathogenesis of sarcopenia in elderly patients undergoing hemodialysis. A total of 40 subjects aged 60 years or more who undergoing hemodialysis in Dr. Soetomo Hospital Surabaya were included in this cross-sectional study. Sarcopenia was diagnosed according to Asian Working Group Sarcopenia 2019 criteria. IGF-1, myostatin, and insulin resistance levels were measured once before hemodialysis. Subjects with sarcopenia diagnosis were 33 (82.5%), that is, 19 (47.5%) men and 14 (35%) women. There were 28 (70%) of the subjects diagnosed with severe sarcopenia. Furthermore, there were significant differences in the characteristics and geriatric parameters between the sarcopenia and nonsarcopenia groups. There were differences between the two groups in hemoglobin levels, IGF-1 levels, myostatin levels, homeostasis model assessment-insulin resistance (HOMA-IR) levels, muscle mass, handgrip strength, body mass index status, mini nutritional assessment status, and physical activity scale for elderly status (all p < 0.05). Correlation analyses showed that IGF-1 levels negatively correlated with sarcopenia status in elderly patients undergoing hemodialysis (p < 0.05). On the contrary, myostatin and HOMA-IR levels were positively correlated with sarcopenia status in elderly patients undergoing hemodialysis (all p < 0.05). Based on this recent study, IGF-1, myostatin, and insulin resistance were significantly correlated with sarcopenia in elderly patients undergoing hemodialysis.

Introduction: Preeclampsia, a serious pregnancy complication, poses significant risks to both maternal and foetal health, potentially leading to morbidity and mortality. This condition is characterised by changes in lipid profiles, hepatic enzymes, Malondialdehyde (MDA), and uric acid levels. Despite significant medical advancements, identifying precise biomarkers for preeclampsia remains complex. Moreover, there is a lack of epidemiological research on preeclampsia within the southern Indian population. Aim: To estimate the levels of serum lipid profiles, hepatic enzyme levels, MDA, and uric acid levels in pregnant women with preeclampsia. Also, to examine the association between MDA and uric acid levels among women with preeclampsia and those with normal pregnancies. Materials and Methods: This cross-sectional study included 162 pregnant patients aged between 18 and 35 years, who attended the Outpatient Department (OPD) or were admitted to a tertiary care hospital in Visakhapatnam, Andhra Pradesh, India between February 2021 and October 2021. The participants were divided into three groups: Group A (54 normotensive pregnant women), Group B (54 pregnant women with non severe preeclampsia), and Group C (54 pregnant women with severe preeclampsia). Lipid profiles, hepatic enzymes, MDA, and uric acid were evaluated in all subjects, and their relationship with preeclampsia severity was assessed. The data were statistically analysed using one-way Analysis of Variance (ANOVA) followed by the Tukey post-hoc test. Results: The study groups (A, B, and C) had comparable age and gestational periods. However, significant variations were observed in lipid profiles, hepatic enzymes, MDA, and uric acid levels among them, which associated with the severity of preeclampsia. Increasing severity was associated with higher cholesterol and triglyceride levels, as well as a decrease in High Density Lipoprotein (HDL) cholesterol. Furthermore, disease progression led to significant elevations in Alkaline Phosphatase (ALP) , uric acid, and MDA levels. In particular, Group A displayed total cholesterol levels of 138.3±20.32 mg/dL, triglycerides of 109.98±15.22 mg/dL, and a negative association with HDLcholesterol at 30.57±3.65 mg/dL. In contrast, Group C exhibited considerably higher levels of total cholesterol, triglycerides, AST, ALT, uric acid, and MDA compared to Group A. Conclusion: As preeclampsia worsens, cholesterol and triglyceride levels increase, while HDL-cholesterol decreases, indicating a deteriorating metabolic profile. Additionally, ALP, uric acid, and MDA levels rise, indicating increased oxidative stress and liver function impact with the progression of the ailment.

T2DM is characterized primarily by pancreatic beta cell loss, inadequate insulin production, or insulin resistance in body cells, among other causes. T2DM is related to a variety of other indications and symptoms including coronary heart disease, kidney illness, eye abnormalities, peripheral vascular disease, digestive system diseases, high blood pressure and depression. Lipid abnormalities are common in persons with type 2 diabetes and prediabetes, although the pattern of the different lipids may vary between ethnic groups, economic levels and access to health care. Uric acid is produced during nucleotide and adenosine triphosphate (ATP) metabolism and is the end product of human purine. Biologically, uric acid plays a significant role in developing insulin resistance in animal models by reducing the bioavailability of nitric oxide which is required for insulin-stimulated glucose uptake. This study aimed to evaluate the lipid profile and uric acid level in patients with Type 2 diabetes mellitus. Blood samples were collected from 50 control and diabetic patients. The lipid profile and uric acid level were estimated by the kit method. Significantly higher levels of total cholesterol, triglycerides, HDL and LDL were observed in the diabetic group compared to the controls. Significantly low levels of serum uric acid and higher blood glucose levels were observed between normal and diabetic subjects. Diabetic dyslipidemia is curable if identified early. It can be improved by regulating glycemic (glucose) levels, lowering free fatty acids and increasing VLDL production by the liver. It can also be treated with weight loss, exercise, smoking cessation, a nutritious diet and pharmaceutical therapy.

We investigated the role of hypoadiponectinemia in the metabolic syndrome (MS), as well as its association with post-glucose challenge hyper-free fatty acidemia in the clinical setting. The study subjects comprised 177 corporate employees shown to have a fasting plasma glucose (FPG) level of 125 mg/dL or less in a 75 g OGTT in the corporation's healthcare center. When divided into those who met the Japanese criteria for the metabolic syndrome (MS group; n = 45) and those who did not (Non-MS group; n = 132), the MS group was shown to have significantly lower adiponectin levels than the Non-MS group, and tended to show higher high-sensitivity C-reactive protein (CRP) values than the Non-MS group, while not achieving statistical significance. The MS group showed higher baseline glucose levels; higher baseline, 30-, 60-, and 120-min post-challenge insulin levels; higher 30-, 60-, and 120-min post-challenge free fatty acid levels than the Non-MS group. Additionally, there was a significant, negative correlation between adiponectin levels, area under the free fatty acid curve, and area under the insulin curve at OGTT (r = -0.24, p < 0.01; r = -0.21, p < 0.01, respectively). When the patients were divided by adiponectin level into four groups to examine the number of risk factors for MS detected per patient and the incidence of MS, the lower the adiponectin level, the more risk factors were found per patient, with 68% of patients with an adiponectin level of less than 4 microg/mL found to have MS. In those with an adiponectin level of less than 4 microg/mL, BMI values, uric acid levels, HOMA-R values, and the number of risk factors for MS involved per patient were shown to be higher than in those with an adiponectin level of 4 microg/mL or greater. Furthermore, the following risk factors for MS were more frequently found in those with an adiponectin level of less than 4 microg/mL than in those with an adiponectin level of 4 microg/mL or greater: VFA > or = 100 cm2 (OR 12.8, p < 0.001); TG > or = 150 mg/dL (OR 3.2, p < 0.05); HDLC < 40 mg/dL (OR 1.9, p = 0.29); BP > or = 130/85 mmHg (OR 2.2, p = 0.15); and FPG > or = 110 mg/dL (OR 1.9, p = 0.29). Again, the incidence of MS (OR 7.6, p < 0.001) by the ATPIII criteria, as well as that by the Japanese criteria (OR 8.6, p < 0.001), was found to be higher in those with an adiponectin level of less than 4 microg/mL than in those with an adiponectin level of 4 microg/mL or greater. Our study results suggest that adiponectin is closely associated with the multiple risk factors that go to make up the MS, suggesting a role for hypoadiponectinemia as a surrogate marker for the MS and further appear to suggest that post-challenge hyper-free fatty acidemia may account in part for hypoadiponectinemia in the MS.

Uric acid is associated with cardiovascular disease (CVD) and its risk factors. Here, we examined the association between the serum uric acid level and incident metabolic syndrome in a Japanese general population. This retrospective, observational study was based on data obtained from an annual health checkup program in Gunma Prefecture, Japan. We evaluated 14,793 participants who did not use antihypertensive or antidiabetic medications and did not present with CVD or metabolic syndrome at the study baseline in 2009. Metabolic syndrome was defined as per the Japanese diagnostic criteria. A discrete proportional hazards regression model was used to evaluate the association between the serum uric acid level at baseline and the incident metabolic syndrome through 2012 and was adjusted for age, gender, waist circumference, systolic and diastolic blood pressure, fasting blood glucose, high-density lipoprotein cholesterol, and triglyceride. At baseline, the average age of the participants was 48.9 years, who were comprised of 40% women. The mean serum uric acid level at baseline was 5.3 ± 1.4 mg/dL. During the three-year follow-up, 7% of the cohort (n = 1,031) developed metabolic syndrome. The uric acid level was strongly associated with incident metabolic syndrome in the multivariable model (adjusted hazard ratio: 1.10; 95% confidence interval, 1.04-1.17; P < 0.01 per 1 mg/dL increase for uric acid). Higher uric acid levels were independently associated with a greater risk of incident metabolic syndrome in a Japanese general population.

The prevalence of metabolic syndrome (MS) increased in recent years in both adolescents and children groups. The aim of the study is evaluating the relationship between insulin and uric acid (UA) level in MS in adolescents we studied 120 adolescence aged 10 to 19 in two groups: control group without metabolic syndrome and case group with metabolic syndrome. The Criteria of ATP III was considered as a diagnosis factor for metabolic syndrome. Various studies have been conducted in various populations to evaluate the relationship between UA level and MS in adolescents. Abdominal obesity, low HDL, hypertriglyceridemia and hypertension are associated with high UA level. In their analysis, the MS OR in UA level⩽4.9, 4.9-5.8 and ⩾5.8 mg/dl was 1, 2.53 and 9.03, respectively, which were higher than our findings in current study. Hyperinsulinemia caused by insulin resistance is one of the complications associated with MS, which puts individuals at risk of diabetes and cardiovascular events. Uric acid level in the Case group was significantly higher than the control group (p = 0.0001, 43.8±1.4 vs. 4.1±1 mg/dl, respectively). Insulin level was significantly higher in the case group in compare to the control group (p = 0.008, 9.8± 5.3 vs. 12.2±6 μU/ml, respectively). The findings of this case-control study showed that adolescents with metabolic syndrome have a higher uric acid and insulin level in compare to normal subjects. We hypothesis that increase in serum insulin and uric acid level can be a risk factor in the development of metabolic syndrome.

Background and ObjectivesAdipokines have been suggested for their potential use in tracking the clinical progress in the subjects with metabolic syndrome (MS). To investigate the relationship between the serum levels of adipokines {adiponectin and retinol-binding protein 4 (RBP4)} and the serum level of uric acid in hypertensive (HTN) patients with MS.Subjects and MethodsIn this study, 38 totally untreated HTN patients were enrolled. Anthropometric measurements, blood pressure (BP) were taken in the 12 HTN patients without MS and the 26 HTN patients with MS. Fasting blood samples were collected for measurement of adiponectin, RBP4, nitric oxide (NO), glucose, creatinine, uric acid, lipid profile and insulin.ResultsThe HTN with MS group had significant higher values of body mass index, waist length, serum uric acid and triglyceride levels than the HTN without MS group. Compared to the HTN without MS group, the HTN with MS group showed significantly lower adiponectin (p=0.030), NO (p=0.003) and high density lipoprotein levels (p<0.001). Serum adiponectin levels negatively correlated with insulin level (R=-0.453, p=0.026) and uric acid level (R=-0.413, p=0.036), and serum RBP4 levels positively correlated with uric acid level (R=0.527, p=0.006) in the HTN with MS group. Multiple linear regression analysis using RBP4 and adiponectin levels as the dependent variables showed that uric acid level correlated with serum RBP4 level (p=0.046) and adiponectin level (p=0.044).ConclusionThe HTN with MS group showed a correlation with two types of adipokines (adiponectin, RBP4) and uric acid. Adiponectin, RBP4 and uric acid may be important components associated with MS, especially when associated with hypertension.

Objectives To investigate the incidence and risk factors of metabolic syndrome(MS) in patients after renal transplantation.Methods 292 renal transplant recipients who had not undergone acute rejection,calcinurine intoxication and severe infection.and had normal renal function and no proteinuria at the 6th month post -transplantation,were involved in the study.They had a history of chronic glomerulonephritis as the primary diseaseof ESRF but no diabetes mellitus.One year after,blood and urine biochemical determinations and physical examination were performed in the recipients,and BMI calculated.200 community residents were randomized selected as controls.Results The incidence of MS in the recipients Was 25.7%,significantly higher than controls(15%).There Was no difference between the incidence of MS in recipients treated with cyclosporine+MMF+prednisone and recipients treated with tacrolimus+MMF+prednisone.The incidence in recipients respectively treated with cyclospo rine at a maintain dosage＞200mg/d or tacrolimus al a maintain dosage＞2mg/d Was markedly higher,compared to cyclosperine at a maintain dosage≤200mg/d or tacrolimus at a maintain dosage≤2mg/d.There was no significant difference between the incidence of obesity or overweight in the recipients and community residents.ConclusionsIt is suggested by the significantly increased incidence of MS that MS might increase the non-immune risk factorsof CAN.It is indicated that,after renal transplantation.male sex and maintain dosage of cyelosporine＞200mg.d1 or a maintain dosage of tacrolimus＞2mg.d-1 are the risk factors of MS after renal transplantation,while obesity and overweiight are not the main factors related to the increased incidence of MS in the sutdy. Key words: Kidney Transplantation; Metabolic Diseases; Syndrome; Risk Factors

Objective To study the relationship between serum uric acid and insulin resistance in type 2 diabetic patients Methods A total of 728 middle-aged and elderly type 2 diabetic patients were recruited and the anthropometric, clinical and biochemical parameters and fasting serum C-peptide were measured and retrospectively studied.All patients were divided into groups based on the levels of uric acid and on metabolic syndrome diagnosis or not. Results Among a total of 728 patients, the proportion of hyperuricemia was 26.9%(196 /728), and metabolic syndrome(MS)was 64.6%.The levels of body mass index(BMI), waist circumference(WC), systolic pressure(SBP), diastolic pressure(DBP), triglyceride(TG), fasting C-peptide, HOMA(C-Peptide)were significantly higher in hyperuricemia group than in normal uric acid group, while the level of HDL was lower in hyperuricemia group than in normal uric acid group.The proportion of MS was statistically higher in hyperuricemia group(81.6%)than in normal uric acid group(58.3%, P<0.05). Groups Ⅰ, Ⅱ, Ⅲ, Ⅳ-the four quartiles of serum uric acid from low-to high-level were correlated with MS component number of 2.1±1.0, 3.1±1.1, 3.3±1.2, 3.7±0.8, separately, and with HOMA(CP)of 3.7±0.8, 3.7±0.8, 4.0±0.6, 4.1±0.9, separately(all P<0.05). When all patients were divided into groups based on with or without MS, the level of uric acid in MS group was(377.3±43.5)μmol/L, and the proportion of hyperuricemia was 34.0%(160/470), and HOMA(CP)was 3.90±0.72, all were significantly higher than those of non-MS group[(318.2±47.9)μmol/L, 14.0%(36/258), 3.64±0.67]. The levels of serum uric acid in groups with 1-5 components of MS were(285.0±62.8)μmol/L, (335.7±62.7)μmol/L, (367.1±45.0)μmol/L, (377.9±40.2)μmol/L, (389.8±46.6)μmol/L, and HOMA(CP)was 3.6±0.6, 3.7±0.7, 3.9±0.8, 3.9±0.7, 4.3±0.7 separately(P<0.05). Serum uric acid was positively correlated with age, WC, BMI, TG, SBP, fasting C-peptide, and HOMA(CP), while negatively correlated with glycosylated hemoglobin(HbA1C), high density lipoprotein cholesterol(HDL-C). Binary logistic regression showed that the OR value of MS was 1.033 with the increase of serum uric acid, and 95%CI: 1.026-1.041, P<0.05. Conclusions Serum uric acid is correlated with insulin resistance in middle-aged and elderly hospitalized patients with type 2 diabetes.Hyperuricemia might be a new risk factor for MS. Key words: Diabetes, type 2; Hyperuricemia; Metabolic syndrome X

Metabolic syndrome (MS) is a cluster of metabolic abnormalities and serves as a precursor of cardiovascular disorders (CVD). The objective of the study was to determine the prevalence of MS and its association with Diabetes mellitus (DM) in an urban setup of Raipur city of Chattishgarh State. A cross sectional study was conducted on 400 randomly selected subjects (men 186, women 214 of age group 10–80 years) in the study region. Anthropometric variables, blood pressure, and lipid profile were monitored besides blood glucose in the study population. The incidence of MS and DM were worked out as per the criteria of National Cholesterol Education Programme-ATPIII (NCEP-ATPIII) and World Health Organization.The incidence of MS was found to be 15% and 5% by ATPIII and WHO criteria respectively. According to NCEP-ATPIII criterion, women recorded significantly high incidence of MS (65%) as compared to males (35%). About 28% of subjects with MS exhibited type II DM (males 16.6% and females 11.6%). On the other hand, the incidence of type II DM was found to be 6.7% in non-metabolic syndrome group of subjects as per NCEP-ATPIII criterion. By WHO criteria, 65% of the subjects with MS exhibited type II DM (males 35% and females 30%) while the incidence is 6.9% in non-metabolic syndrome group of subjects. Subjects in age group of 41–65 years showed the highest incidence of MS irrespective of the criteria employed. The incidence of MS differed significantly by the two criteria employed and it was more by NCEP-ATP-III criteria. The prevalence of type II DM was significantly high in subjects with metabolic syndrome and it was more in males of age group of 41–65 yrs.